Citations (57)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Jane Castelli-Haley, MerriKay A. Oleen-Burkey, Maureen J. Lage & Kenneth Johnson. (2010) Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts. Journal of Medical Economics 13:3, pages 464-471.
Read now
Read now
Felix Mor & Alon Monsonego. (2006) Immunization therapy in Alzheimer's disease. Expert Review of Neurotherapeutics 6:5, pages 653-659.
Read now
Read now
Jerry S Wolinsky. (2004) Glatiramer acetate for the treatment of multiple sclerosis. Expert Opinion on Pharmacotherapy 5:4, pages 875-891.
Read now
Read now
. (2003) Novel peptides for the treatment of multiple sclerosis. Expert Opinion on Therapeutic Patents 13:1, pages 119-123.
Read now
Read now
Banu Anlar. (2002) Childhood multiple sclerosis: course and management. Expert Review of Neurotherapeutics 2:3, pages 339-345.
Read now
Read now
Articles from other publishers (52)
Rina Aharoni. 2022. Peptide and Peptidomimetic Therapeutics. Peptide and Peptidomimetic Therapeutics
507
520
.
Thomas Prod’homme & Scott S. Zamvil. (2019) The Evolving Mechanisms of Action of Glatiramer Acetate. Cold Spring Harbor Perspectives in Medicine 9:2, pages a029249.
Crossref
Crossref
Iris Grossman, Sarah Kolitz, Arthur Komlosh, Benjamin Zeskind, Vera Weinstein, Daphna Laifenfeld, Adrian Gilbert, Oren Bar-Ilan, Kevin D. Fowler, Tal Hasson, Attila Konya, Kevin Wells-Knecht, Pippa Loupe, Sigal Melamed-Gal, Tatiana Molotsky, Revital Krispin, Galia Papir, Yousif Sahly & Michael R. Hayden. (2017)
Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation
ex vivo
in a mouse model
. Annals of the New York Academy of Sciences 1407:1, pages 75-89.
Crossref
Crossref
Ye-Hyeon Ahn, Sae-Bom Jeon, Chi Young Chang, Eun-Ah Goh, Sang Soo Kim, Ho Jin Kim, Jaewhan Song & Eun Jung Park. (2017) Glatiramer acetate attenuates the activation of CD4+ T cells by modulating STAT1 and −3 signaling in glia. Scientific Reports 7:1.
Crossref
Crossref
Vera Weinstein, Rivka Schwartz, Iris Grossman, Benjamin Zeskind & J. Michael Nicholas. 2015. Non-Biological Complex Drugs. Non-Biological Complex Drugs
107
148
.
Spencer Moore, Anna J. Khalaj, Rhusheet Patel, JaeHee Yoon, Daniel Ichwan, Liat Hayardeny & Seema K. Tiwari‐Woodruff. (2014) Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate. Journal of Neuroscience Research 92:12, pages 1621-1636.
Crossref
Crossref
Madhan Thamilarasan, Michael Hecker, Robert Hermann Goertsches, Brigitte Katrin Paap, Ina Schröder, Dirk Koczan, Hans-Jürgen Thiesen & Uwe Klaus Zettl. (2013) Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients. Journal of Neuroinflammation 10:1.
Crossref
Crossref
Richard Reynolds & Robert Crichton. 2013. Mechanisms and Metal Involvement in Neurodegenerative Diseases. Mechanisms and Metal Involvement in Neurodegenerative Diseases
163
185
.
Katherine Buzzard, Simon Broadley & Helmut Butzkueven. (2012) What Do Effective Treatments for Multiple Sclerosis Tell Us about the Molecular Mechanisms Involved in Pathogenesis?. International Journal of Molecular Sciences 13:12, pages 12665-12709.
Crossref
Crossref
Yehuda Shoenfeld. (2011) The Future of Autoimmunity. Clinical Reviews in Allergy & Immunology 42:2, pages 113-120.
Crossref
Crossref
Xiaohong Chen, Xiaomeng Ma, Ying Jiang, Rongbiao Pi, Yingying Liu & Lili Ma. (2011) The prospects of minocycline in multiple sclerosis. Journal of Neuroimmunology 235:1-2, pages 1-8.
Crossref
Crossref
Mrinalini Kala, Augusto Miravalle & Timothy Vollmer. (2011) Recent insights into the mechanism of action of glatiramer acetate. Journal of Neuroimmunology 235:1-2, pages 9-17.
Crossref
Crossref
Augusto MiravalleBarry HendinTimothy L. VollmerMrinalini Kala. (2011) Glatiramer Acetate in the Reduction of Relapse Frequency in Multiple Sclerosis. Clinical Medicine Insights: Therapeutics 3, pages CMT.S2057.
Crossref
Crossref
Rakel CarpinteroKarim J. BrandtLyssia GruazNicolas MolnarfiPatrice H. Lalive & Danielle Burger. (2010) Glatiramer acetate triggers PI3Kδ/Akt and MEK/ERK pathways to induce IL-1 receptor antagonist in human monocytes. Proceedings of the National Academy of Sciences 107:41, pages 17692-17697.
Crossref
Crossref
Reza Vosoughi & Mark S. Freedman. (2010) Therapy of MS. Clinical Neurology and Neurosurgery 112:5, pages 365-385.
Crossref
Crossref
Dimitros Karussis, Dvora Teitelbaum, Camille Sicsic & Talma Brenner. (2010) Long-term treatment of multiple sclerosis with glatiramer acetate: Natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy. Journal of Neuroimmunology 220:1-2, pages 125-130.
Crossref
Crossref
Chunhua Chen, Xuebin Liu, Bing Wan & Jingwu Z. Zhang. (2009) Regulatory Properties of Copolymer I in Th17 Differentiation by Altering STAT3 Phosphorylation. The Journal of Immunology 183:1, pages 246-253.
Crossref
Crossref
Jane Castelli-Haley, MerriKay A. Oleen-Burkey, Maureen J. Lage & Kenneth P. Johnson. (2009) Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis. Advances in Therapy 26:5, pages 552-562.
Crossref
Crossref
Danielle BurgerNicolas MolnarfiMartin S. WeberKarim J. BrandtMahdia Benkhoucha, Lyssia GruazMichel Chofflon, Scott S. ZamvilPatrice H. Lalive. (2009) Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1β in human monocytes and multiple sclerosis. Proceedings of the National Academy of Sciences 106:11, pages 4355-4359.
Crossref
Crossref
L. I. Reikhert, O. A. Kicherova, A. A. Sokolova & Zsh. I. Molchanova. (2009) The basis of membrane stabilized effect of kopaxon in multiple sclerosis. Bulletin of Siberian Medicine 8:1(2), pages 64-68.
Crossref
Crossref
Jane Castelli-Haley, Merry-Kay A. Oleen-Burkey, Maureen J. Lage & Kenneth P. Johnson. (2008) Glatiramer acetate versus interferon beta-1a for subcutaneous administration: Comparison of outcomes among multiple sclerosis patients. Advances in Therapy 25:7, pages 658-673.
Crossref
Crossref
Swati Acharya & C. Garrison Fathman. 2008. Regulatory T Cells and Clinical Application. Regulatory T Cells and Clinical Application
231
252
.
Jianuo Liu, Thomas V. Johnson, Jamie Lin, Servio H. Ramirez, Tatiana K. Bronich, Steve Caplan, Yuri Persidsky, Howard E. Gendelman & Jonathan Kipnis. (2007) T cell independent mechanism for copolymer-1-induced neuroprotection. European Journal of Immunology 37:11, pages 3143-3154.
Crossref
Crossref
Ruth Arnon & Rina Aharoni. (2007) Neurogenesis and Neuroprotection in the CNS — Fundamental Elements in the Effect of Glatiramer Acetate on Treatment of Autoimmune Neurological Disorders. Molecular Neurobiology 36:3, pages 245-253.
Crossref
Crossref
Maddalena Ruggieri, Carlo Avolio, Paolo Livrea & Maria Trojano. (2007) Glatiramer Acetate in Multiple Sclerosis: A Review. CNS Drug Reviews 13:2, pages 178-191.
Crossref
Crossref
D. Teitelbaum, R. Arnon & M. Sela. 2007. Comprehensive Medicinal Chemistry II. Comprehensive Medicinal Chemistry II
173
185
.
Katharina Maier, Antje V. Kuhnert, Naimeh Taheri, Muriel B. Sättler, Maria K. Storch, Sarah K. Williams, Mathias Bähr & Ricarda Diem. (2006) Effects of Glatiramer Acetate and Interferon-β on Neurodegeneration in a Model of Multiple Sclerosis. The American Journal of Pathology 169:4, pages 1353-1364.
Crossref
Crossref
Daniel Larocque & Josée Bergeron. 2006. Gene Therapy for Neurological Disorders. Gene Therapy for Neurological Disorders
213
227
.
Michael Sela. (2006) Immunomodulatory Vaccines Against Autoimmune Diseases. Rejuvenation Research 9:1, pages 126-133.
Crossref
Crossref
RUTH ARNON. 2006. Handbook of Biologically Active Peptides. Handbook of Biologically Active Peptides
603
610
.
Rina Aharoni, Basak Kayhan & Ruth Arnon. (2005) Therapeutic Effect of the Immunomodulator Glatiramer Acetate on Trinitrobenzene Sulfonic Acid-Induced Experimental Colitis. Inflammatory Bowel Diseases 11:2, pages 106-115.
Crossref
Crossref
Michel Chofflon. (2005) Mechanisms of Action for Treatments in??Multiple Sclerosis. BioDrugs 19:5, pages 299-308.
Crossref
Crossref
Fabrizio Giuliani, Luanne M. Metz, Tammy Wilson, Yan Fan, Amit Bar-Or & V. Wee Yong. (2005) Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. Journal of Neuroimmunology 158:1-2, pages 213-221.
Crossref
Crossref
Rina Aharoni, Alexander Yussim, Michael Sela & Ruth Arnon. (2005) Combined treatment of glatiramer acetate and low doses of immunosuppressive drugs is effective in the prevention of graft rejection. International Immunopharmacology 5:1, pages 23-32.
Crossref
Crossref
M. Schwartz. 2005. Regenerative and Cell Therapy. Regenerative and Cell Therapy
81
96
.
DVORA TEITELBAUM, RINA AHARONI, ETY KLINGER, RIVKA KREITMAN, EMANUEL RAYMOND, ARTHUR MALLEY, RONA SHOFTI, MICHAEL SELA & RUTH ARNON. (2004) Oral Glatiramer Acetate in Experimental Autoimmune Encephalomyelitis: Clinical and Immunological Studies. Annals of the New York Academy of Sciences 1029:1, pages 239-249.
Crossref
Crossref
Michael Sela & Edna Mozes. (2004) Therapeutic vaccines in autoimmunity. Proceedings of the National Academy of Sciences 101:suppl_2, pages 14586-14592.
Crossref
Crossref
Michael Sela. 2004. Selected Topics in the History of Biochemistry Personal Recollections. VIII. Selected Topics in the History of Biochemistry Personal Recollections. VIII
1
100
.
M. Schwartz. 2004. Neuroinflammation in Stroke. Neuroinflammation in Stroke
133
154
.
D TeitelbaumT Brenner, O Abramsky, R Aharoni, M Sela & R Arnon. (2016) Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Multiple Sclerosis Journal 9:6, pages 592-599.
Crossref
Crossref
Michael Sela. (2003) From Proteins and Protein Models to Their Use in Immunology and Immunotherapy. Journal of Biological Chemistry 278:49, pages 48507-48519.
Crossref
Crossref
Man Chen, Reuben Mari Valenzuela & Suhayl Dhib-Jalbut. (2003) Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. Journal of the Neurological Sciences 215:1-2, pages 37-44.
Crossref
Crossref
Ruth Arnon & Michael Sela. (2003) Immunomodulation by the copolymer glatiramer acetate. Journal of Molecular Recognition 16:6, pages 412-421.
Crossref
Crossref
Dennis N Schmitz, Nils Hofmann, Toma L Tomov, Adam D Kovac, Wolfram F Neiss & Doychin N Angelov. (2003) The correlation between severity of paraparesis and reduced density of resident antigen-presenting cells implicates an unknown role for the spinal perivascular macrophages in experimental autoimmune encephalomyelitis in rats. Journal of Neuroimmunology 142:1-2, pages 31-46.
Crossref
Crossref
Suhayl Dhib-Jalbut. (2003) Glatiramer acetate (Copaxone®) therapy for multiple sclerosis. Pharmacology & Therapeutics 98:2, pages 245-255.
Crossref
Crossref
Dene Simpson, Stuart Noble & Caroline Perry. (2003) Spotlight on Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis1. BioDrugs 17:3, pages 207-210.
Crossref
Crossref
Michal Schwartz. 2003. Mind over Matter - Regulation of Peripheral Inflammation by the CNS. Mind over Matter - Regulation of Peripheral Inflammation by the CNS
3
18
.
V. Wee Yong. (2002) Differential mechanisms of action of interferon-β and glatiramer acetate in MS. Neurology 59:6, pages 802-808.
Crossref
Crossref
Jonathan Kipnis & Michal Schwartz. (2002) Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders. Trends in Molecular Medicine 8:7, pages 319-323.
Crossref
Crossref
Michael Sela, Ruth Arnon & Bilha Schechter. (2002) Therapeutic vaccines: realities of today and hopes for the future. Drug Discovery Today 7:12, pages 664-673.
Crossref
Crossref
Douglas L. Feinstein, Elena Galea, Vitaliy Gavrilyuk, Celia F. Brosnan, Caroline C. Whitacre, Lucia Dumitrescu-Ozimek, Gary E. Landreth, Harrihar A. Pershadsingh, Guy Weinberg & Michael T. Heneka. (2002) Peroxisome proliferator-activated receptor-? agonists prevent experimental autoimmune encephalomyelitis. Annals of Neurology 51:6, pages 694-702.
Crossref
Crossref
Dene Simpson, Stuart Noble & Caroline Perry. (2002) Glatiramer Acetate. CNS Drugs 16:12, pages 825-850.
Crossref
Crossref